Glycostem listed in independent article
November 2016;
Glycostem is delighted that we have been listed as the only not-public listed company in this article. If you are interested in the NK cell space, this is a recommended read.
NK 2016 16th Meeting of Society for Natural Immunity
October 2-5, 2016
Glycostem presented their recent advances in NK cell therapy for hematological and solid cancers at NK 2016.
Annual Discovery on Target Event, Boston
September 19-22, 2016
Glycostem's CSO, Dr. Jan Spanholtz, has been invited as speaker at the 14th Annual Discovery on Target Event, Boston, USA
CTIP Conference Hamburg
June 27-28, 2016
Dr. Jan Spanholtz (CSO) presents at the 5th Clinical Trials Innovation Programme Conference (CTIP), Hamburg, Germany
BIO International Convention San Francisco
June 6-9, 2016
Dr. Wim Jongen (CEO) represents Glycostem at the BIO International Convention in San Francisco, USA
Health Valley Event, Pivot Park Oss
June 2, 2016
Dr. Jan Spanholtz (CSO) gives a presentation on Innovative Cellular Medicine at the Health Valley Event Exit Oss: 'Crossing Borders', Pivot Park, Oss, The Netherlands
Innate Killer Summit
May 16-18, 2016
Dr. Jan Spanholtz (CSO) presents results of clinical phase I study at the Innate Killer Summit, San Diego, USA
Orphan-Drug Designation request of NK Cell Product oNKord® granted by FDA
April 20, 2016
On the 20th of April 2016, the FDA Office of Orphan Products Development has granted orphan drug designation to Glycostem's NK Cell Product oNKord® for treatment of acute myeloid leukemia (AML)
Adopt Summit
March 1-3, 2016
Glycostem's CSO, Dr. Jan Spanholtz presents clinical phase I data at the Adopt Summit 2016: Adoptive Immunotherapy, London, UK
Biotech Showcase San Francisco
Jan 11-13, 2016
Glycostem will be represented at Biotech Showcase, the 8th Annual Biotechnology Investor and Partnering Conference, San Francisco, USA.
Wim Jongen (CEO) and Jan Spanholtz (CFO) will participate.
ASH Annual Meeting
December 4-8, 2015
Glycostem together with Radboud University Medical Center presents results of their Phase I clinical trial in AML patients at the 57th ASH Annual Meeting, Orlando, USA
Poster presentation by Dr. Harry Dolstra and Dr. Jan Spanholtz
Bio-Europe
November 2-4, 2015
Glycostem's CEO, Dr. Wim Jongen, gives a company presentation at Bio-Europe, Munich, Germany
Natural Killer Cell Symposium
October 7-9, 2016
Dr. Jan Spanholtz and John Veluchamy attend the Natural Killer Cell Symposium, Göttingen, Germany. John Veluchamy (PhD fellow) will present a poster at this meeting.
Sachs Forum
September 29-30, 2015
Glycostem's CEO, Dr. Wim Jongen, gives a company presentation at 15th Annual Biotech in Europe Forum, Basel, Switzerland
Health Valley Event, Pivot Park Oss
July 9, 2015
Glycostem's CSO, Dr. Jan Spanholtz, gives a presentation on Cell Therapy in Oncology at the Health Valley Event Exit Oss, Pivot Park, Oss, The Netherlands
NK2015
May 2-6, 2015
Glycostem's CSO, Dr. Jan Spanholtz, presents Poster at NK2015, 15th Annual Meeting of the Society for Natural Immunity, Montebello, Québec, Canada
Glycostem launches its new website
On the 2nd December Glycostem has officially launched its new website, which provides a comprehensive overview of our current position and ambitious plans on the application of NK cell immunotherapy in the treatment of cancer.
Read more >Glycostem's NK Cell Product oNKord® received Orphan drug designation for AML
ODD for NK Cell Product oNKord® to treat AML
Read more >